Year in Review: Clinical Trials in Cardiology During COVID-19


Deepak Bhatt, MD, MPH, offers his perspective on how the ongoing pandemic has influenced clinical trials during 2020 and whether he thinks any changes will persist beyond the COVID-19 era.

As part of our Year in Review series, Practical Cardiology reached out to experts across the field of cardiovascular medicine to offer their perspective on advances during 2020. In the following video, Deepak Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital, who breaks down his perspective on how COVID-19 has impacted clinical trials in the space.

A leading investigator in a multitude of clinical trials prior to the pandemic, Bhatt also led two trials (SCORED and SOLOIST-WHF) that were cut short due to funding during the pandemic and even presented a trial at NLA 2020 examining icosapent ethyl in outpatients with COVID-19. In our interview, Bhatt dives deeper into his experiences as a trialist in 2020 and how clinical trials will be different in the future due to COVID-19.

Recent Videos
Brendon Neuen, MBBS, PhD | Credit:
A panel of 5 cardiovascular experts
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
Video 3 - "Aligning With 2023 ESC Guidelines in oHCM Treatment"
Robert Rosenson, MD | Credit: Cura Foundation
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
© 2024 MJH Life Sciences

All rights reserved.